Skip to main content
Erschienen in: Cancer Causes & Control 10/2007

01.12.2007 | Original Paper

Use of antidepressants and risk of lung cancer

verfasst von: Sengwee Toh, Luis A. García Rodríguez, Sonia Hernández-Díaz

Erschienen in: Cancer Causes & Control | Ausgabe 10/2007

Einloggen, um Zugang zu erhalten

Abstract

Objective

To evaluate the effect of antidepressant use on lung cancer risk.

Methods

We conducted a case–control study nested in a cohort of patients 40–84 year-old in 1995–2004, without a prior diagnosis of cancer using The Health Improvement Network (THIN) database in the UK. Cases comprised 4,336 patients with a first diagnosis of primary lung cancer. A sample of 10,000 controls was frequency-matched to the cases for age, sex, and the calendar year of diagnosis. The index date for exposure definition was one year before the diagnosis for cases and one year before a random date for controls. Odds ratios (ORs) and 95% confidence intervals (CIs) were estimated using conditional logistic regression models adjusted for potential confounders.

Results

Selective serotonin reuptake inhibitor (SSRI) use during the year preceding the index date with treatment duration of at least one year had an OR of 0.59 (95% CI 0.41, 0.86). The corresponding OR was 1.23 (95% CI 0.96, 1.58) for tricyclic antidepressants (TCAs).

Conclusions

SSRI use did not increase the lung cancer risk and might be associated with a reduced risk. However, residual confounding might explain the apparent protective effect found for SSRI use, as well as the marginally elevated risk observed among TCA users.
Literatur
1.
Zurück zum Zitat Brandes LJ, Arron RJ, Bogdanovic RP et al (1992) Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52:3796–3800PubMed Brandes LJ, Arron RJ, Bogdanovic RP et al (1992) Stimulation of malignant growth in rodents by antidepressant drugs at clinically relevant doses. Cancer Res 52:3796–3800PubMed
2.
Zurück zum Zitat Wright SC, Zhong J, Larrick JW (1994) Inhibition of apoptosis as a mechanism of tumor promotion. Faseb J 8:654–660PubMed Wright SC, Zhong J, Larrick JW (1994) Inhibition of apoptosis as a mechanism of tumor promotion. Faseb J 8:654–660PubMed
3.
Zurück zum Zitat Eisen JN, Irwin J, Quay J, Livnat S (1989) The effect of antidepressants on immune function in mice. Biol Psychiatry 26:805–817PubMedCrossRef Eisen JN, Irwin J, Quay J, Livnat S (1989) The effect of antidepressants on immune function in mice. Biol Psychiatry 26:805–817PubMedCrossRef
4.
Zurück zum Zitat Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ (2003) Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 3:169–184PubMedCrossRef Volpe DA, Ellison CD, Parchment RE, Grieshaber CK, Faustino PJ (2003) Effects of amitriptyline and fluoxetine upon the in vitro proliferation of tumor cell lines. J Exp Ther Oncol 3:169–184PubMedCrossRef
5.
Zurück zum Zitat Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM (1992) Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 52:6931–6935PubMed Bendele RA, Adams ER, Hoffman WP, Gries CL, Morton DM (1992) Carcinogenicity studies of fluoxetine hydrochloride in rats and mice. Cancer Res 52:6931–6935PubMed
6.
Zurück zum Zitat Parchment RE, Machado S, Balch A et al (1992) Lack of stimulation of murine tumor growth by antidepressants and antihistamines (abstract). Proc Am Assoc Cancer Res 37:160 Parchment RE, Machado S, Balch A et al (1992) Lack of stimulation of murine tumor growth by antidepressants and antihistamines (abstract). Proc Am Assoc Cancer Res 37:160
7.
Zurück zum Zitat Abdul M, Logothetis CJ, Hoosein NM (1995) Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154:247–250PubMedCrossRef Abdul M, Logothetis CJ, Hoosein NM (1995) Growth-inhibitory effects of serotonin uptake inhibitors on human prostate carcinoma cell lines. J Urol 154:247–250PubMedCrossRef
8.
Zurück zum Zitat Freire-Garabal M, Nunez MJ, Pereiro D et al (1998) Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci 63:PL31–PL38PubMedCrossRef Freire-Garabal M, Nunez MJ, Pereiro D et al (1998) Effects of fluoxetine on the development of lung metastases induced by operative stress in rats. Life Sci 63:PL31–PL38PubMedCrossRef
9.
Zurück zum Zitat Serafeim A, Holder MJ, Grafton G et al (2003) Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212–3219PubMedCrossRef Serafeim A, Holder MJ, Grafton G et al (2003) Selective serotonin reuptake inhibitors directly signal for apoptosis in biopsy-like Burkitt lymphoma cells. Blood 101:3212–3219PubMedCrossRef
10.
Zurück zum Zitat Rosetti M, Frasnelli M, Tesei A, Zoli W, Conti M (2006) Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. J Exp Ther Oncol 6:23–29PubMed Rosetti M, Frasnelli M, Tesei A, Zoli W, Conti M (2006) Cytotoxicity of different selective serotonin reuptake inhibitors (SSRIs) against cancer cells. J Exp Ther Oncol 6:23–29PubMed
11.
Zurück zum Zitat Harlow BL, Cramer DW (1995) Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case–control studies (Massachusetts, United States). Cancer Causes Control 6:130–134PubMedCrossRef Harlow BL, Cramer DW (1995) Self-reported use of antidepressants or benzodiazepine tranquilizers and risk of epithelial ovarian cancer: evidence from two combined case–control studies (Massachusetts, United States). Cancer Causes Control 6:130–134PubMedCrossRef
12.
Zurück zum Zitat Harlow BL, Cramer DW, Baron JA, Titus-Ernstoff L, Greenberg ER (1998) Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 7:697–702PubMed Harlow BL, Cramer DW, Baron JA, Titus-Ernstoff L, Greenberg ER (1998) Psychotropic medication use and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 7:697–702PubMed
13.
Zurück zum Zitat Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE (2000) Psychotropic medication use and risk of hormone-related cancers: the New York University Women’s Health Study. J Public Health Med 22:155–160PubMedCrossRef Kato I, Zeleniuch-Jacquotte A, Toniolo PG, Akhmedkhanov A, Koenig K, Shore RE (2000) Psychotropic medication use and risk of hormone-related cancers: the New York University Women’s Health Study. J Public Health Med 22:155–160PubMedCrossRef
14.
Zurück zum Zitat Steingart A, Cotterchio M, Kreiger N, Sloan M (2003) Antidepressant medication use and breast cancer risk: a case–control study. Int J Epidemiol 32:961–966PubMedCrossRef Steingart A, Cotterchio M, Kreiger N, Sloan M (2003) Antidepressant medication use and breast cancer risk: a case–control study. Int J Epidemiol 32:961–966PubMedCrossRef
15.
Zurück zum Zitat Cotterchio M, Kreiger N, Darlington G, Steingart A (2000) Antidepressant medication use and breast cancer risk. Am J Epidemiol 151:951–957PubMed Cotterchio M, Kreiger N, Darlington G, Steingart A (2000) Antidepressant medication use and breast cancer risk. Am J Epidemiol 151:951–957PubMed
16.
Zurück zum Zitat Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14:307–314PubMedCrossRef Moorman PG, Grubber JM, Millikan RC, Newman B (2003) Antidepressant medications and their association with invasive breast cancer and carcinoma in situ of the breast. Epidemiology 14:307–314PubMedCrossRef
17.
Zurück zum Zitat Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR (2006) Antidepressant use and breast cancer risk. Breast Cancer Res Treat 95:131–140PubMedCrossRef Chien C, Li CI, Heckbert SR, Malone KE, Boudreau DM, Daling JR (2006) Antidepressant use and breast cancer risk. Breast Cancer Res Treat 95:131–140PubMedCrossRef
18.
Zurück zum Zitat Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 162:835–838PubMedCrossRef Coogan PF, Palmer JR, Strom BL, Rosenberg L (2005) Use of selective serotonin reuptake inhibitors and the risk of breast cancer. Am J Epidemiol 162:835–838PubMedCrossRef
19.
Zurück zum Zitat Coogan PF, Rosenberg L, Palmer JR et al (2000) Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). Cancer Causes Control 11:839–845PubMedCrossRef Coogan PF, Rosenberg L, Palmer JR et al (2000) Risk of ovarian cancer according to use of antidepressants, phenothiazines, and benzodiazepines (United States). Cancer Causes Control 11:839–845PubMedCrossRef
20.
Zurück zum Zitat Dublin S, Rossing MA, Heckbert SR, Goff BA, Weiss NS (2002) Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control 13:35–45PubMedCrossRef Dublin S, Rossing MA, Heckbert SR, Goff BA, Weiss NS (2002) Risk of epithelial ovarian cancer in relation to use of antidepressants, benzodiazepines, and other centrally acting medications. Cancer Causes Control 13:35–45PubMedCrossRef
21.
Zurück zum Zitat Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS (2006) Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 94:1071–1078PubMedCrossRef Fulton-Kehoe D, Rossing MA, Rutter C, Mandelson MT, Weiss NS (2006) Use of antidepressant medications in relation to the incidence of breast cancer. Br J Cancer 94:1071–1078PubMedCrossRef
22.
Zurück zum Zitat González-Pérez A, García Rodríguez LA (2005) Breast cancer risk among users of antidepressant medications. Epidemiology 16:101–105PubMedCrossRef González-Pérez A, García Rodríguez LA (2005) Breast cancer risk among users of antidepressant medications. Epidemiology 16:101–105PubMedCrossRef
23.
Zurück zum Zitat Kelly JP, Rosenberg L, Palmer JR et al (1999) Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 150:861–868PubMed Kelly JP, Rosenberg L, Palmer JR et al (1999) Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am J Epidemiol 150:861–868PubMed
24.
Zurück zum Zitat Moorman PG, Berchuck A, Calingaert B, Halabi S, Schildkraut JM (2005) Antidepressant medication use [corrected] and risk of ovarian cancer. Obstet Gynecol 105:725–730PubMed Moorman PG, Berchuck A, Calingaert B, Halabi S, Schildkraut JM (2005) Antidepressant medication use [corrected] and risk of ovarian cancer. Obstet Gynecol 105:725–730PubMed
25.
Zurück zum Zitat Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J (2001) Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 54:728–734PubMedCrossRef Wang PS, Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J (2001) Antidepressant use and the risk of breast cancer: a non-association. J Clin Epidemiol 54:728–734PubMedCrossRef
26.
Zurück zum Zitat Dalton SO, Johansen C, Mellemkjaer L et al (2000) Antidepressant medications and risk for cancer. Epidemiology 11:171–176PubMedCrossRef Dalton SO, Johansen C, Mellemkjaer L et al (2000) Antidepressant medications and risk for cancer. Epidemiology 11:171–176PubMedCrossRef
27.
Zurück zum Zitat Xu W, Tamim H, Shapiro S, Stang MR, Collet JP (2006) Use of antidepressants and risk of colorectal cancer: a nested case–control study. Lancet Oncol 7:301–308PubMedCrossRef Xu W, Tamim H, Shapiro S, Stang MR, Collet JP (2006) Use of antidepressants and risk of colorectal cancer: a nested case–control study. Lancet Oncol 7:301–308PubMedCrossRef
28.
Zurück zum Zitat Theoharides TC, Konstantinidou A (2003) Antidepressants and risk of cancer: a case of misguided associations and priorities. J Clin Psychopharmacol 23:1–4PubMedCrossRef Theoharides TC, Konstantinidou A (2003) Antidepressants and risk of cancer: a case of misguided associations and priorities. J Clin Psychopharmacol 23:1–4PubMedCrossRef
29.
Zurück zum Zitat Lawrenson RA, Tyrer F, Newson RB, Farmer RD (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59:149–157PubMedCrossRef Lawrenson RA, Tyrer F, Newson RB, Farmer RD (2000) The treatment of depression in UK general practice: selective serotonin reuptake inhibitors and tricyclic antidepressants compared. J Affect Disord 59:149–157PubMedCrossRef
30.
Zurück zum Zitat Ornstein S, Stuart G, Jenkins R (2000) Depression diagnoses and antidepressant use in primary care practices: a study from the practice partner research network (PPRNet). J Fam Pract 49:68–72PubMed Ornstein S, Stuart G, Jenkins R (2000) Depression diagnoses and antidepressant use in primary care practices: a study from the practice partner research network (PPRNet). J Fam Pract 49:68–72PubMed
31.
Zurück zum Zitat Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef Jemal A, Siegel R, Ward E et al (2006) Cancer statistics, 2006. CA Cancer J Clin 56:106–130PubMedCrossRef
32.
Zurück zum Zitat Hernández-Díaz S, García-Rodríguez LA (2007) Non-steroidal anti-inflammatory drugs and the risk of lung cancer. Int J Cancer 120:1565–1572PubMedCrossRef Hernández-Díaz S, García-Rodríguez LA (2007) Non-steroidal anti-inflammatory drugs and the risk of lung cancer. Int J Cancer 120:1565–1572PubMedCrossRef
33.
Zurück zum Zitat Psaty BM, Koepsell TD, Lin D et al (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749–754PubMed Psaty BM, Koepsell TD, Lin D et al (1999) Assessment and control for confounding by indication in observational studies. J Am Geriatr Soc 47:749–754PubMed
34.
Zurück zum Zitat Knekt P, Raitasalo R, Heliovaara M et al (1996) Elevated lung cancer risk among persons with depressed mood. Am J Epidemiol 144:1096–1103PubMed Knekt P, Raitasalo R, Heliovaara M et al (1996) Elevated lung cancer risk among persons with depressed mood. Am J Epidemiol 144:1096–1103PubMed
35.
Zurück zum Zitat Covey LS, Glassman AH, Stetner F (1998) Cigarette smoking and major depression. J Addict Dis 17:35–46PubMedCrossRef Covey LS, Glassman AH, Stetner F (1998) Cigarette smoking and major depression. J Addict Dis 17:35–46PubMedCrossRef
36.
Zurück zum Zitat Klungsoyr O, Nygard JF, Sorensen T, Sandanger I (2006) Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. Am J Epidemiol 163:421–432PubMedCrossRef Klungsoyr O, Nygard JF, Sorensen T, Sandanger I (2006) Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. Am J Epidemiol 163:421–432PubMedCrossRef
37.
Zurück zum Zitat Cofta-Woerpel L, Wright KL, Wetter DW (2006) Smoking cessation 1: pharmacological treatments. Behav Med 32:47–56PubMedCrossRef Cofta-Woerpel L, Wright KL, Wetter DW (2006) Smoking cessation 1: pharmacological treatments. Behav Med 32:47–56PubMedCrossRef
38.
Zurück zum Zitat Hughes JR, Stead LF, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No. CD000031 Hughes JR, Stead LF, Lancaster T (2004) Antidepressants for smoking cessation. Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No. CD000031
39.
Zurück zum Zitat Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA (2002) National trends in the outpatient treatment of depression. JAMA 287:203–209PubMedCrossRef Olfson M, Marcus SC, Druss B, Elinson L, Tanielian T, Pincus HA (2002) National trends in the outpatient treatment of depression. JAMA 287:203–209PubMedCrossRef
40.
Zurück zum Zitat Stafford RS, MacDonald EA, Finkelstein SN (2001) National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 3:232–235PubMed Stafford RS, MacDonald EA, Finkelstein SN (2001) National patterns of medication treatment for depression, 1987 to 2001. Prim Care Companion J Clin Psychiatry 3:232–235PubMed
41.
Zurück zum Zitat Mittmann N, Herrmann N, Einarson TR et al (1997) The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 46:191–217PubMedCrossRef Mittmann N, Herrmann N, Einarson TR et al (1997) The efficacy, safety and tolerability of antidepressants in late life depression: a meta-analysis. J Affect Disord 46:191–217PubMedCrossRef
42.
Zurück zum Zitat Song F, Freemantle N, Sheldon TA et al (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306:683–687PubMed Song F, Freemantle N, Sheldon TA et al (1993) Selective serotonin reuptake inhibitors: meta-analysis of efficacy and acceptability. BMJ 306:683–687PubMed
Metadaten
Titel
Use of antidepressants and risk of lung cancer
verfasst von
Sengwee Toh
Luis A. García Rodríguez
Sonia Hernández-Díaz
Publikationsdatum
01.12.2007
Verlag
Springer Netherlands
Erschienen in
Cancer Causes & Control / Ausgabe 10/2007
Print ISSN: 0957-5243
Elektronische ISSN: 1573-7225
DOI
https://doi.org/10.1007/s10552-007-9045-1

Weitere Artikel der Ausgabe 10/2007

Cancer Causes & Control 10/2007 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.